Travel Medicine

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/30/2023
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/30/2023
FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/30/2023
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/30/2023
FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/30/2023
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/30/2023
FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023